Literature DB >> 23040011

Anatomic brain disease in hemodialysis patients: a cross-sectional study.

David A Drew1, Rafeeque Bhadelia, Hocine Tighiouart, Vera Novak, Tammy M Scott, Kristina V Lou, Kamran Shaffi, Daniel E Weiner, Mark J Sarnak.   

Abstract

BACKGROUND: Although dialysis patients are at high risk of stroke and have a high burden of cognitive impairment, there are few reports of anatomic brain findings in the hemodialysis population. Using magnetic resonance imaging of the brain, we compared the prevalence of brain abnormalities in hemodialysis patients with that in a control population without known kidney disease. STUDY
DESIGN: Cross-sectional cohort. SETTING & PARTICIPANTS: 45 maintenance hemodialysis patients and 67 controls without reported kidney disease, both without history of known stroke. PREDICTOR: The primary predictor was dialysis status. Covariates included demographics (age, race, and sex), vascular risk factors (diabetes and hypertension), and cardiovascular disease (coronary artery disease and congestive heart failure). OUTCOMES: Magnetic resonance imaging of the brain features, including severity of white matter disease and cerebral atrophy (sulcal prominence and ventricular atrophy), hippocampal size, and small-/large-vessel infarcts. MEASUREMENTS: Semiquantitative scale (0-9 for white matter disease and cerebral atrophy, 0-3 for hippocampal size) and infarct prevalence.
RESULTS: Mean ages of hemodialysis patients and controls were 55 ± 17 (SD) and 53 ± 13 years, respectively. In comparison to controls, hemodialysis patients had more severe white matter disease (1.6 vs 0.7) and cerebral atrophy (sulcal prominence, 2.3 vs 0.6; ventricular enlargement, 2.3 vs 0.9; hippocampal size, 1.3 vs 1.0), with all P < 0.001. In multivariable analyses, hemodialysis status was associated independently with worse white matter disease and atrophy grades. Hemodialysis patients also had a higher prevalence of small- (17.8%) and large- (7.8%) vessel infarcts than controls (combined, 22% vs 0%; P < 0.001). LIMITATIONS: The dialysis cohort likely is healthier than the overall US hemodialysis population, partly limiting generalizability.
CONCLUSIONS: Hemodialysis patients have more white matter disease and cerebral atrophy compared with controls without known kidney disease. Hemodialysis patients also have a high prevalence of unrecognized infarcts.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040011      PMCID: PMC3546146          DOI: 10.1053/j.ajkd.2012.08.035

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  39 in total

Review 1.  Hyperhomocysteinemia in chronic renal disease.

Authors:  A G Bostom; B F Culleton
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

2.  Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery.

Authors:  I Stefanidis; R Bach; P R Mertens; V Liakopoulos; G Liapi; H Mann; B Heintz
Journal:  Clin Nephrol       Date:  2005-08       Impact factor: 0.975

3.  Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment.

Authors:  G Fazekas; F Fazekas; R Schmidt; P Kapeller; H Offenbacher; G J Krejs
Journal:  J Neurol Sci       Date:  1995-12       Impact factor: 3.181

4.  Cerebral magnetic resonance T2 high intensities in end-stage renal disease.

Authors:  M Suzuki; A Wada; Y Isaka; K Maki; T Inoue; Y Fukuhara
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

5.  Sulcal, ventricular, and white matter changes at MR imaging in the aging brain: data from the cardiovascular health study.

Authors:  N C Yue; A M Arnold; W T Longstreth; A D Elster; C A Jungreis; D H O'Leary; V C Poirier; R N Bryan
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

6.  Infarctlike lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly--data from the Cardiovascular Health Study.

Authors:  R N Bryan; S W Wells; T J Miller; A D Elster; C A Jungreis; V C Poirier; B K Lind; T A Manolio
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

7.  Cognitive impairment in hemodialysis patients is common.

Authors:  A M Murray; D E Tupper; D S Knopman; D T Gilbertson; S L Pederson; S Li; G E Smith; A K Hochhalter; A J Collins; R L Kane
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

8.  Subcortical cognitive impairment in dialysis patients.

Authors:  Arema A Pereira; Daniel E Weiner; Tammy Scott; Priya Chandra; Robyn Bluestein; John Griffith; Mark J Sarnak
Journal:  Hemodial Int       Date:  2007-07       Impact factor: 1.812

9.  Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study.

Authors:  T A Manolio; R A Kronmal; G L Burke; V Poirier; D H O'Leary; J M Gardin; L P Fried; E P Steinberg; R N Bryan
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

10.  Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study.

Authors:  M M Breteler; N M van Amerongen; J C van Swieten; J J Claus; D E Grobbee; J van Gijn; A Hofman; F van Harskamp
Journal:  Stroke       Date:  1994-06       Impact factor: 7.914

View more
  51 in total

1.  Near-infrared spectroscopy underestimates cerebral oxygenation in hemodialysis patients.

Authors:  Shino Matsukawa; Shinichi Kai; Toshiyuki Mizota
Journal:  J Anesth       Date:  2019-05-06       Impact factor: 2.078

Review 2.  Symptom Management of the Patient with CKD: The Role of Dialysis.

Authors:  Valerie Jorge Cabrera; Joni Hansson; Alan S Kliger; Fredric O Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

3.  Immediate Abnormal Intrinsic Brain Activity Patterns in Patients with End-stage Renal Disease During a Single Dialysis Session : Resting-state Functional MRI Study.

Authors:  Cong Peng; Hua Yang; Qian Ran; Ling Zhang; Chengxuan Liu; Yu Fang; Yingjiang Liu; Yi Cao; Renrong Liang; He Ren; Qinqin Hu; Xiuting Mei; Yang Jiang; Tianyou Luo
Journal:  Clin Neuroradiol       Date:  2020-07-03       Impact factor: 3.649

4.  Fluid management: the challenge of defining standards of care.

Authors:  Jennifer E Flythe; M Alan Brookhart
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

5.  Evaluation of Screening Tests for Cognitive Impairment in Patients Receiving Maintenance Hemodialysis.

Authors:  David A Drew; Hocine Tighiouart; Jasmine Rollins; Sarah Duncan; Seda Babroudi; Tammy Scott; Daniel E Weiner; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 10.121

Review 6.  Cognitive and physical function in chronic kidney disease.

Authors:  Daniel E Weiner; Stephen L Seliger
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-05       Impact factor: 2.894

7.  Reduced speed of microvascular blood flow in hemodialysis patients versus healthy controls: a coherent hemodynamics spectroscopy study.

Authors:  Michele L Pierro; Jana M Kainerstorfer; Amanda Civiletto; Daniel E Weiner; Angelo Sassaroli; Bertan Hallacoglu; Sergio Fantini
Journal:  J Biomed Opt       Date:  2014-02       Impact factor: 3.170

8.  Dementia, Alzheimer's Disease, and Mortality after Hemodialysis Initiation.

Authors:  Mara A McAdams-DeMarco; Matthew Daubresse; Sunjae Bae; Alden L Gross; Michelle C Carlson; Dorry L Segev
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-09       Impact factor: 8.237

Review 9.  Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.

Authors:  David A Drew; Daniel E Weiner; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2019-08-01       Impact factor: 8.860

10.  Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis.

Authors:  Manjula Kurella Tamura; Glenn M Chertow; Thomas A Depner; Allen R Nissenson; Brigitte Schiller; Ravindra L Mehta; Sai Liu; Tammy L Sirich
Journal:  J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.